Trial: 201905076

An Open-label, Randomized, Multicenter Study Evaluating the Activity of Lasofoxifene Relative to Fulvestrant for the Treatment of
Postmenopausal Women with Locally Advanced or Metastatic ER+/HER2-Breast Cancer with an ESR1 Mutation

Phase

II

Principal Investigator

Bagegni, Nusayba

Disease Site

Breast

Learn more about this study at: clinicaltrials.gov